Phase 2 Results That Led to Phase 3 Retatrutide's Phase 2 trial results, published in the New England Journal of Medicine in June 2023, were strong enough that Eli Lilly fast-tracked it into one of the largest Phase 3 obesity programs ever run
CNS Drugs 39 , 937947 (2025)
Challenges Hindering GLP-1 Nutritional Support Growth Despite the growing demand, the industry faces challenges related to gastrointestinal side effects, which affect up to 50% of GLP-1 users
Last updated June 3, 2026 Editorial policy From Weight Loss Clinics to Addiction Labs The trajectory of GLP-1 receptor agonists has taken a turn that few in the pharmaceutical world predicted
Latest Products Golden Glo Your one stop shop
It can cause side effects such as nausea, vomiting, stomach upset, heartburn, diarrhea, and seizures